(Seattle) Delmar Pharma (DMPI) Announces Presentation of Positive VAL-083 Data as Ovarian Cancer Treatment Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Wednesday, September 14, 2016

(Seattle) Delmar Pharma (DMPI) Announces Presentation of Positive VAL-083 Data as Ovarian Cancer Treatment



financial news

DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) announced that the Company and its collaborators from the University of Texas MD Anderson Cancer Center presented new data in a research poster entitled "Activity of dianhydrogalactitol (VAL-083) in ovarian tumor models, sensitive or resistant to cisplatin" at the 11th Biennial Ovarian Cancer Research Symposium.
The data, presented on the evening of Monday, September 12th at the Rivkin Center for Ovarian Cancer in Seattle, Washington, support a distinct mechanism of action for VAL-083 versus platinum-based chemotherapy currently used in the treatment of ovarian cancer.....

0 comments :

Post a Comment

Your comments?